Clinical Trial

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Study acronym: EMERALD-3
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally. The study will last up to approximately 108 weeks, excluding screening.
Protocol Amendment History 3 changes
notable Trial sites expanded: 253 -> 256 locations 2026-07-08
critical Recruitment opened 2026-04-23
notable Trial sites expanded: 241 -> 251 locations 2026-04-23
Trial Details
NCT Number NCT07415044
Lead Sponsor Eli Lilly and Company
Conditions Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Enrollment 1,431 participants
Start Date 2026-03-26
Primary Completion 2030-06 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2026-08-06